中国螺旋断层放疗治疗鼻咽癌的临床研究：5年结果
Clinical study of nasopharyngeal carcinoma treated by helical tomotherapy in China: 5-year outcomes.
作者信息
Du Lei, Zhang Xin-Xin, Ma Lin, Feng Lin-Chun, Li Fang, Zhou Gui-Xia, Qu Bao-Lin, Xu Shou-Ping, Xie Chuan-Bin, Yang Jack
机构信息
Department of Radiation Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China ; Department of Radiation Oncology, Hainan Branch of Chinese PLA General Hospital, Haitang Bay, Sanya 572000, China.
Department of Otorhinolaryngology, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.
出版信息
Biomed Res Int. 2014;2014:980767. doi: 10.1155/2014/980767. Epub 2014 Jul 9.
BACKGROUND
To evaluate the outcomes of nasopharyngeal carcinoma (NPC) patients treated with helical tomotherapy (HT).
METHODS
Between September 2007 and August 2012, 190 newly diagnosed NPC patients were treated with HT. Thirty-one patients were treated with radiation therapy as single modality, 129 with additional cisplatin-based chemotherapy with or without anti-EGFR monoclonal antibody therapy, and 30 with concurrent anti-EGFR monoclonal antibody therapy.
RESULTS
Acute radiation related side effects were mainly grade 1 or 2. Grade 3 and greater toxicities were rarely noted. The median followup was 32 (3-38) months. The local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), distant metastasis-free survival (DMFS), and overall survival (OS) were 96.1%, 98.2%, 92.0%, and 86.3%, respectively, at 3 years. Cox multivariate regression analysis showed that age and T stage were independent predictors for 3-year OS.
CONCLUSIONS
Helical tomotherapy for NPC patients achieved excellent 3-year locoregional control, distant metastasis-free survival, and overall survival, with relatively minor acute and late toxicities. Age and T stage were the main prognosis factors.
背景
评估接受螺旋断层放射治疗（HT）的鼻咽癌（NPC）患者的治疗结果。
方法
2007年9月至2012年8月期间，190例新诊断的NPC患者接受了HT治疗。31例患者仅接受放射治疗，129例接受了以顺铂为基础的化疗，联合或不联合抗表皮生长因子受体（EGFR）单克隆抗体治疗，30例接受了同步抗EGFR单克隆抗体治疗。
结果
急性放射相关副作用主要为1级或2级。很少观察到3级及以上毒性反应。中位随访时间为32（3 - 38）个月。3年时局部无复发生存率（LRFS）、区域淋巴结无复发生存率（NRFS）、远处转移无复发生存率（DMFS）和总生存率（OS）分别为96.1%、98.2%、92.0%和86.3%。Cox多因素回归分析显示，年龄和T分期是3年总生存率的独立预测因素。
结论
NPC患者接受螺旋断层放射治疗可获得出色的3年局部区域控制率、远处转移无复发生存率和总生存率，且急、慢性毒性相对较小。年龄和T分期是主要的预后因素。
Zotero 插件